Results 31 to 40 of about 150,246 (305)

A single-center retrospective cohort study of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma

PLoS ONE, 2022
Background Diffuse malignant peritoneal mesothelioma (DMPM) is a rare variant of malignant mesothelioma, representing 10–15% of malignant mesothelioma cases.
Xiao Wang, Sharyn Katz, John Miura, Giorgos Karakousis, Leonid Roshkovan, Suzanne Walker, Sally McNulty, Christine Ciunci, Keith Cengel, Corey J. Langer, Melina E. Marmarelis   +10 more
doaj   +2 more sources

A single arm phase II trial of neoadjuvant cabazitaxel and cisplatin chemotherapy for muscle invasive transitional cell carcinoma of the urinary bladder

, 2021
Introduction: Neoadjuvant cisplatin-based combination chemotherapy improves survival in muscle-invasive bladder cancer. However, response rates and survival remain suboptimal.
Pearson, Sylvia, Persad, Raj, Bravo, Alicia, Bahl, Amit, Masson, Susan, Perks, Claire, Ash-Miles, Janice, Dailami, Narges, Foulstone, Emily, Koupparis, Anthony, Challapalli, Amarnath, Holly, Jeff, Abdelaziz, Ahmed, Oxley, Jon, Rowe, Edward, White, Paul   +15 more
core   +1 more source

The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy

Scientific Reports, 2022
Neoadjuvant immunotherapy and chemotherapy have improved the major pathological response (MPR) in patients with early-stage operable non-small cell lung cancer (NSCLC).
Po-Lan Su, Jung-Yueh Chen, Chang-Yao Chu, Yi-Lin Chen, Wan-Li Chen, Kuan-Yu Lin, Chung-Liang Ho, Jeng-Shiuan Tsai, Szu-Chun Yang, Chian-Wei Chen, Yi-Lin Wu, Yau-Lin Tseng, Chao-Chun Chang, Yi-Ting Yen, Chia-Ying Lin, Chien-Chung Lin, Wu-Chou Su   +16 more
doaj   +1 more source

Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients : analysis of >4,500 patients from four German randomized breast cancer trials [PDF]

, 2008
Introduction: Despite the fact that people older than 65 years of age have the highest incidence of developing breast cancer, these patients are excluded from clinical trials in most cases.
Kümmel, Sherko, Sibylle Loibl, Gunter von Minckwitz, Kuemmel, Sherko, Valentina Nekljudova, Marion Kiechle, Elling, Dirk, Holm Eggemann, Harald Sommer, Janni, Wolfgang, Sommer, Harald, Wolfgang Janni, Loibl, Sibylle, Nadia Harbeck, Manfred Kaufmann, Harbeck, Nadia, Nekljudova, Valentina, Minckwitz, Gunter von, Sherko Kümmel, Kiechle, Marion, Kaufmann, Manfred, Eggemann, Holm, Dirk Elling   +22 more
core   +1 more source

Neoadjuvant chemotherapy in advanced-stage ovarian cancer – state of the art

Menopause Review, 2022
Ovarian cancer represents the fifth cause of cancer death among women, carrying one of the worst prognoses among gynaecological malignancies. The need to achieve no residual disease after surgery in order to optimize prognosis of advanced-stage ovarian ...
Chrysoula Margioula-Siarkou, Stamatios Petousis, Alexios Papanikolaou, Giuseppe Gullo, Georgia Margioula-Siarkou, Antonio Simone Laganà, Konstantinos Dinas, Frederic Guyon   +7 more
doaj   +1 more source

Neoadjuvant Chemotherapy Improves the Immunosuppressive Microenvironment of Bladder Cancer and Increases the Sensitivity to Immune Checkpoint Blockade

Journal of Immunology Research, 2022
Although tumor immune microenvironment plays an important role in antitumor therapy, few studies explored the gene signatures associated with the tumor immune microenvironment of bladder cancer after neoadjuvant chemotherapy.
Hao Luo, Gao-Lei Liu, Dan Jian, Dan-Dan Liang, Xue-Mei Li, Li Zhong, Bo Yang, Jun Jiang, Dong Wang, Meng-Xia Li, Wei-Hua Lan, Nan Dai   +11 more
doaj   +1 more source

Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma

Radiation Oncology, 2019
Purpose Neoadjuvant chemoradiation or chemotherapy has improved the treatment efficacy of patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma (PDAC).
Qiancheng Hu, Dan Wang, Ye Chen, Xiaofen Li, Peng Cao, Dan Cao   +5 more
doaj   +1 more source

Bayesian network meta-analysis of efficacy and safety of neoadjuvant therapy for non-small-cell lung cancer

Therapeutic Advances in Medical Oncology, 2020
Objective: Neoadjuvant chemotherapy has increased the survival benefit of non-small cell lung cancer (NSCLC) patients. The effects of different neoadjuvant therapies are still controversial. We carried out the study to evaluate the efficacy and safety of
Yijiu Ren, Hai Tang, Jie Zhang, Yunlang She, Xiaoting Sun, Dong Xie, Chang Chen   +6 more
doaj   +1 more source

The Impact of Neoadjuvant versus Adjuvant Chemotherapy on Survival Outcomes in Locally Advanced Breast Cancer

Current Oncology
The utility of neoadjuvant chemotherapy is expanding in the treatment of breast cancer. Although individual trials have shown comparable survival between patients receiving neoadjuvant and adjuvant chemotherapy, large-scale data analyses for outcomes in ...
Farhad Ghasemi, Muriel Brackstone
doaj   +1 more source

Noninvasive assessment of response to neoadjuvant chemotherapy in osteosarcoma of long bones with diffusion-weighted imaging: an initial in vivo study. [PDF]

PLoS ONE, 2013
OBJECTIVES: The purpose of our study is to investigate whether diffusion-weighted imaging (DWI) is useful for monitoring the therapeutic response after neoadjuvant chemotherapy in osteosarcoma of long bones.
Cheng-Sheng Wang, Lian-Jun Du, Ming-Jue Si, Qi-Hua Yin, Liang Chen, Min Shu, Fei Yuan, Xiao-Chun Fei, Xiao-Yi Ding   +8 more
doaj   +1 more source